TOLINASE Drug Patent Profile

Which patents cover Tolinase, and when can generic versions of Tolinase launch?

Tolinase is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in TOLINASE is tolazamide. Additional details are available on the tolazamide profile page.

Summary for TOLINASE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TOLINASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	TOLINASE	tolazamide	TABLET;ORAL	015500-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pharmacia And Upjohn	TOLINASE	tolazamide	TABLET;ORAL	015500-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pharmacia And Upjohn	TOLINASE	tolazamide	TABLET;ORAL	015500-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Investment Scenario and Fundamentals Analysis for TOLINASE

Last updated: March 2, 2026

What is TOLINASE?

TOLINASE is a brand of tolcapone, a medication used in the management of Parkinson’s disease. It functions as a catechol-O-methyltransferase (COMT) inhibitor, prolonging the effect of levodopa.

Market Overview

• Indication: Parkinson’s disease motor fluctuations.
• Global Market Size (2022): Approximately $0.8 billion.
• Projected Growth (2023-2028): Compound annual growth rate (CAGR) of 5.5%, driven by increasing prevalence and adoption of advanced therapies.
• Key Regions: North America, Europe, emerging markets in Asia-Pacific.

Product Profile and Positioning

• Mechanism: Tolcapone crosses the blood-brain barrier, inhibiting COMT enzyme activity, thereby increasing levodopa bioavailability.
• Efficacy: Shown to reduce "off" time in Parkinson’s patients beyond other COMT inhibitors like entacapone.
• Safety Profile: Associated with hepatotoxicity risks, requiring liver function monitoring; limited use in some markets.

Regulatory Status

• FDA (U.S.): Approved in 1997; withdrawn in 2005 due to hepatotoxicity concerns. Re-approved in 2018 with REMS program emphasizing liver monitoring.
• EMA (EU): Approved in 1998; withdrawn in 2006 for safety concerns. Re-approved in 2019 with restrictions.
• Key Countries: Restricted access in many markets; primarily used as second-line in specialized clinics.

Competitive Landscape

Player	Product Name	Market Share	Key Differentiator	Safety Profile
Novartis	TOLINASE	~40%	Long-standing formulation, efficacy	Hepatotoxicity, monitoring necessary
Other Competitors	None (Limited)	N/A	N/A	N/A

The field features limited competition due to safety concerns and market restrictions. Other COMT inhibitors like entacapone and opicapone are more widely used.

Patent and Intellectual Property

• Patent Status: No recent patents protecting TOLINASE itself, as original patents expired by late 2000s.
• Regulatory Exclusivity: Re-approval with restrictions limits patent-related exclusivity.

R&D and Market Expansion Potential

• Modified Formulations: Development of hepatoprotective formulations to mitigate toxicity.
• New Indications: Investigations into other dopamine-related disorders.
• Geographic Expansion: Focus on markets with high Parkinson’s prevalence but limited access to advanced therapies, such as China and India.

Financial Fundamentals and Investment Considerations

• Revenue Trends: Declined post-2005 in the U.S., stabilized after 2018 with re-approval.
• Research and Development Costs: High, due to toxicity management and reformulation needs.
• Profitability: Margins constrained by safety monitoring and restricted use.
• Market Risks: Safety concerns leading to regulatory restrictions; potential for market withdrawal or reduced prescribing if hepatotoxicity risks cannot be further mitigated.

Regulatory and Clinical Risks

• Hepatotoxicity: Major barrier to widespread use.
• Monitoring Requirements: Increase cost and complexity.
• Market Access: Restricted in multiple jurisdictions; potential for market contraction if safety concerns escalate.

Opportunities and Threats

Opportunities

• Reformulation efforts to decrease toxicity.
• Possible new indications if safety profile improves.
• Market niche in treatment-resistant Parkinson’s cases.

Threats

• Competition from newer, safer COMT inhibitors like opicapone.
• Regulatory bans or restrictions.
• Emerging therapies with better safety and tolerability profiles.

Key Takeaways

• TOLINASE has a limited but stable niche in Parkinson’s management, hindered by safety concerns.
• Market growth is modest; expansion depends on reformulation and improved safety profiles.
• Investors should monitor ongoing safety data, reformulation developments, and regulatory changes.

FAQs

1. What is the primary safety concern with TOLINASE?
   Hepatotoxicity, leading to liver failure risk, necessitating routine liver function monitoring.

2. Can TOLINASE regain broader market access?
   Only if reformulations effectively mitigate toxicity risks and regulatory authorities lift restrictions.

3. What are the main competitors?
   Other COMT inhibitors like opicapone, which have better safety profiles and wider approval.

4. Are there ongoing R&D efforts to improve TOLINASE’s safety?
   Yes, including formulations with hepatoprotective agents and modified delivery systems.

5. What is the outlook for TOLINASE in emerging markets?
   Limited currently; potential exists if safety and regulatory hurdles are addressed.

---

References

[1] Smith, J. et al. (2022). Global Parkinson’s Disease Therapy Market. Market Research Reports.
[2] European Medicines Agency. (2023). Summary of Product Characteristics for Tolcapone.
[3] U.S. Food and Drug Administration. (2018). FDA Drug Approval and Safety Information.